Most drug companies remain to be convinced that new screens can predict drugs' properties as well as or better than existing methods. They also don't know whether cells can be produced reliably in sufficient quantities for screening, and whether regulatory agencies will accept data derived from them.
Roche says that it is already running screens based on stem cells to test drugs for cardiotoxicity and effects on neurogenesis. Matthias Steger, the company's global business development director for stemcell alliances, says that under the latest deal, Harvard and Massachusetts General Hospital will work on embryonic stem cells and iPS cells derived from individuals with various forms of cardiovascular disease. The institutions will receive milestone payments as screens are validated, and the collaboration will last 3-5 years. Ruth McKernan, chief scientific officer of Pfizer's regenerative medicine unit, notes that although screens based on stem cells will be useful, they are not the main reason that Pfizer is interested in these cells. "This progress, though important, is incremental when compared to the real promise in using these cells as therapeutics," she says. ■ 
Monya Baker
Testing time for stem cells with scepticism from experts. Last December, an Indiana physician named Gary Erdy told Illinois officials he had a new photograph of an ivory-billed woodpecker from the same area. They later revoked his search permit.
Meanwhile, experts are dealing with protests by Daniel Rainsong, a landscaper based in Ames, Iowa, who says he recently photographed an ivory-billed woodpecker near the Sabine River in east Texas. Rainsong filed a formal complaint earlier this month alleging ethical and financial misconduct, because biologists he approached would not come with him to the Sabine region to confirm the sighting so that he could collect a $50,000 reward.
Rohrbaugh says the Cornell team will release an analysis of Rainsong's photo in about a week.
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